Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel

First Posted Date: 2004-09-06

Last Posted Date: 2020-04-29

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 2005

Registration Number: NCT00003088

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States

and more 16 locations

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-03

Last Posted Date: 2010-01-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 70

Registration Number: NCT00002937

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada

and more 1 locations

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 50

Registration Number: NCT00002628

Locations: 🇺🇸
Methodist Hospital-Central Unit, Memphis, Tennessee, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-08-26

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 45

Registration Number: NCT00003378

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 61 locations

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2004-08-25

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 55

Registration Number: NCT00003237

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 27 locations

Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

Phase 3

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-08-24

Last Posted Date: 2013-06-21

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00002888

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 84 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-08-24

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT00002711

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-24

Last Posted Date: 2012-07-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 60

Registration Number: NCT00002969

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States

and more 82 locations

Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-16

Last Posted Date: 2013-06-26

Lead Sponsor: State University of New York - Upstate Medical University

Target Recruit Count: 20

Registration Number: NCT00003555

Locations: 🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

Phase 1

Conditions: Drug/Agent Toxicity by Tissue/Organ
Head and Neck Cancer
Radiation Toxicity

First Posted Date: 2004-08-13

Last Posted Date: 2013-12-04

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 46

Registration Number: NCT00003251

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy